Editorial
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Virology. Aug 12, 2015; 4(3): 169-177
Published online Aug 12, 2015. doi: 10.5501/wjv.v4.i3.169
Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics
Victor Asensi, Julio Collazos, Eulalia Valle-Garay
Victor Asensi, Infectious Diseases-HIV Unit, Hospital Universitario Central de Asturias, Oviedo University School of Medicine, 33013 Oviedo, Spain
Julio Collazos, Infectious Diseases Unit, Hospital de Galdácano, 48960 Vizcaya, Spain
Eulalia Valle-Garay, Biochemistry and Molecular Biology Department, Oviedo University School of Medicine, 33006 Oviedo, Spain
Author contributions: All authors contributed to this paper.
Conflict-of-interest statement: The authors do not have any conflict of interest related to this paper.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Victor Asensi, MD, PhD, Infectious Diseases-HIV Unit, Hospital Universitario Central de Asturias, Oviedo University School of Medicine, Avenida de Roma s/n, 33013 Oviedo, Spain. vasensia@gmail.com
Telephone: +34-985-108000-36442
Received: January 15, 2015
Peer-review started: January 16, 2015
First decision: April 27, 2015
Revised: May 8, 2015
Accepted: June 9, 2015
Article in press: June 11, 2015
Published online: August 12, 2015
Processing time: 210 Days and 9.4 Hours
Core Tip

Core tip: Pharmacogenetics may play an important role in the near future for the treatment of human immunodeficiency virus-infection, as exemplified by the HLAB*5701 genotyping to prevent the abacavir-associated hypersensitivity reaction. Diverse other single nucleotide polymorphisms have been described as related to certain pharmacokinetic characteristics and adverse effects of antiretroviral drugs. In this Editorial we summarize the current knowledge on this rapidly evolving field.